Key result
Type-5 Cardiorenal Syndrome is a recently defined clinical syndrome characterized by concomitant renal and cardiovascular dysfunction secondary to systemic conditions.
This review provides an update on the epidemiology, pathophysiology, clinical presentation, and therapeutic approaches for type-5 cardiorenal syndrome.
Type-5 cardiorenal syndrome warrants consideration in systemic diseases; leaves open prospective validation of diagnostic and therapeutic strategies.
Cardiorenal syndromes (CRS) involve disorders of the heart or kidney whereby one organ dysfunction leads to the dysfunction of another. Five types of CRS are defined. While the first 4 types describe acute/chronic cardiorenal or renocardiac syndromes, type-5 CRS refers to secondary CRS or cardiorenal involvement in systemic conditions and describes the concomitant presence of renal and cardiovascular dysfunction. Type-5 CRS is a recently defined clinical syndrome and complete epidemiological data on this entity are still lacking. In the following review, epidemiological, pathophysiological, clinical, and therapeutic approaches to type-5 CRS will be discussed according to more recent findings.
No takes yet. Share an insight, caveat, or question.
Lullo et al. (2017) conducted a review in Type-5 Cardiorenal Syndrome (CRS-5). Type-5 Cardiorenal Syndrome is a recently defined clinical syndrome characterized by concomitant renal and cardiovascular dysfunction secondary to systemic conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: